{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"31","value":"106500"},{"groupId":"OG001","spread":"30","value":"27250"},{"groupId":"OG002","spread":"45","value":"4673"},{"groupId":"OG003","spread":"34","value":"23520"},{"groupId":"OG004","spread":"24","value":"26960"},{"groupId":"OG005","spread":"39","value":"23780"},{"groupId":"OG006","spread":"39","value":"20790"},{"groupId":"OG007","spread":"28","value":"20570"},{"groupId":"OG008","spread":"35","value":"26020"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"19"},{"groupId":"OG008","value":"9"},{"groupId":"OG009","value":"0"}],"units":"Participants"}],"title":"Cycle 1/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"126","value":"15940"},{"groupId":"OG001","spread":"93","value":"4584"},{"groupId":"OG002","spread":"38","value":"1070"},{"groupId":"OG003","spread":"73","value":"5740"},{"groupId":"OG004","spread":"60","value":"7344"},{"groupId":"OG005","spread":"56","value":"8692"},{"groupId":"OG006","spread":"35","value":"5036"},{"groupId":"OG007","spread":"41","value":"6671"},{"groupId":"OG008","spread":"135","value":"7185"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"26"},{"groupId":"OG004","value":"27"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"0"}],"units":"Participants"}],"title":"Cycle 1/Day8-168 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19","value":"132000"},{"groupId":"OG001","spread":"19","value":"26250"},{"groupId":"OG002","spread":"58","value":"6446"},{"groupId":"OG003","spread":"26","value":"26210"},{"groupId":"OG004","spread":"31","value":"28880"},{"groupId":"OG005","spread":"21","value":"35950"},{"groupId":"OG006","spread":"26","value":"15170"},{"groupId":"OG007","spread":"66","value":"20190"},{"groupId":"OG008","spread":"35","value":"27710"},{"groupId":"OG009","spread":"21","value":"26710"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"16"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"9"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"7"}],"units":"Participants"}],"title":"Cycle 3/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29","value":"134800"},{"groupId":"OG001","spread":"70","value":"26470"},{"groupId":"OG002","spread":"48","value":"5800"},{"groupId":"OG003","spread":"51","value":"32630"},{"groupId":"OG004","spread":"25","value":"28370"},{"groupId":"OG005","spread":"36","value":"28000"},{"groupId":"OG006","spread":"98","value":"11270"},{"groupId":"OG007","spread":"48","value":"19440"},{"groupId":"OG008","spread":"30","value":"25650"},{"groupId":"OG009","spread":"141","value":"15410"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"14"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"7"}],"units":"Participants"}],"title":"Cycle 5/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28","value":"121800"},{"groupId":"OG001","spread":"951","value":"13340"},{"groupId":"OG002","spread":"20","value":"6067"},{"groupId":"OG003","spread":"85","value":"38930"},{"groupId":"OG004","spread":"92","value":"19870"},{"groupId":"OG005","spread":"38","value":"20710"},{"groupId":"OG006","spread":"22","value":"20710"},{"groupId":"OG007","spread":"34","value":"16750"},{"groupId":"OG008","spread":"22","value":"21680"},{"groupId":"OG009","spread":"89","value":"18080"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"5"}],"units":"Participants"}],"title":"Cycle 8/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30","value":"124800"},{"groupId":"OG001","spread":"62","value":"19800"},{"groupId":"OG002","spread":"26","value":"6892"},{"groupId":"OG003","spread":"225","value":"44690"},{"groupId":"OG004","spread":"8","value":"20460"},{"groupId":"OG005","spread":"28","value":"27030"},{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG007","spread":"NA","value":"12900"},{"groupId":"OG008","spread":"33","value":"20730"},{"groupId":"OG009","spread":"1","value":"24060"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"3"},{"groupId":"OG009","value":"3"}],"units":"Participants"}],"title":"Cycle 12/Day1-1 Hour/EOI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"32"},{"groupId":"OG005","value":"21"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"20"},{"groupId":"OG008","value":"10"},{"groupId":"OG009","value":"7"}],"units":"Participants"}],"description":"Cmax is maximum observed plasma concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"During phase 1b participants with Non-Small Cell Lung Cancer (NSCLC) received utomilumab 500 mg intravenously (IV) every 4 weeks (Q4W) with 10 milligrams per kilogram (mg/kg) of avelumab administered IV every 2 weeks (Q2W) for 2 cycles, where each cycle was of 4 weeks.","id":"OG000","title":"Combination A Phase 1b NSCLC: Utomilumab 500 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG001","title":"Combination A Phase 1b NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During phase 1b participants with NSCLC received utomilumab 20 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG002","title":"Combination A Phase 1b NSCLC: Utomilumab 20 mg + Avelumab"},{"description":"During Phase 2 participants with melanoma received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG003","title":"Combination A Phase 2 Melanoma: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous Cell Carcinoma of the Head and Neck (SCCHN) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG004","title":"Combination A Phase 2 SCCHN: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Triple Negative Breast Cancer (TNBC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG005","title":"Combination A Phase 2 TNBC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with Squamous cell lung cancer (SCLC) received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG006","title":"Combination A Phase 2 SCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG007","title":"Combination A Phase 2 First Line (1L) NSCLC: Utomilumab 100 mg + Avelumab"},{"description":"During Phase 2 participants with NSCLC received utomilumab 100 mg IV Q4W for cycle 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"OG008","title":"Combination A Phase 2 1L NSCLC: Utomilumab Then Utomilumab + Avelumab"},{"description":"During Phase 2 participants with NSCLC received avelumab 10 mg/kg administered IV Q2W for cycles 1 then utomilumab 100 mg IV Q4W with 10 mg/kg of avelumab administered IV Q2W starting at cycle 2.","id":"OG009","title":"Combination A Phase 2 1L NSCLC: Avelumab Then Utomilumab + Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who received at least one dose of study drug and who had at least one of the PK concentrations for Avelumab, Utomilumab, PD 0360324, PF-04518600. Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure, where \"Number Analyzed\" signifies number of participants evaluable for specified time points. For participants of ''Phase 2 1L NSCLC: Avelumab then Utomilumab + Avelumab'' reporting group PK sampling started from Cycle 3 Day 1.","reportingStatus":"POSTED","timeFrame":"1-hour post-infusion (at end of infusion) on Day 1 of Cycle 1,3,5,8,12; Day 8 of Cycle 1 (non-dosing). For ''Phase 2 1L NSCLC: Avelumab then Utomilumab + Avelumab'' reporting group: Day 1 of Cycle 3,5,8,12","title":"Maximum Observed Plasma Concentration (Cmax) of Utomilumab in Combination A","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}